Naftopidil appears to have similar effects in the urological symptom scores and QoL compared to tamsulosin and silodosin .
Naftopidil has similar sexual adverse events compared to tamsulosin but has fewer compared to silodosin
BACKGROUND Benign prostatic hyperplasia ( BPH ) is a common condition in ageing men that may cause lower urinary tract symptoms ( LUTS ) .
Treatment aims are to relieve symptoms and prevent disease-related complications .
Naftopidil is an alpha-blocker ( AB ) that has a high affinity for the A1d receptor that may have advantages in treating LUTS in this setting .
This is an up date of a Cochrane Review first published in 2009 .
Since that time , several large r and omised controlled trials ( RCTs ) have been reported , making this up date relevant .
OBJECTIVES To evaluate the effects of naftopidil for the treatment of LUTS associated with BPH .
Comparison of Silodosin and Naftopidil for Efficacy in the Treatment of Benign Prostatic Enlargement Complicated by Overactive Bladder: A Randomized, Prospective Study (SNIPER Study)
Purpose : We investigated the efficacy of 2 & agr;1‐blockers with different affinities for the & agr;1‐adrenoceptor subtypes silodosin and naftopidil in the treatment of benign prostatic enlargement complicated by overactive bladder . Material s and Methods : This was a prospect i ve , open label , r and omized , multicenter study of 350 out patients with untreated benign prostatic enlargement associated with urinary urgency at least once per week and an OABSS ( Overactive Bladder Symptom Score ) of 3 or greater . Patients were r and omly assigned to receive silodosin 8 mg per day or naftopidil 75 mg per day . Changes in parameters from baseline to 4 and 12 weeks were assessed based on I‐PSS ( International Prostate Symptom Score ) , I‐PSS quality of life , OABSS and voiding functions measured by uroflowmetry . Results : On efficacy analysis a total of 314 patients were included in the 2 groups . No significant difference in adverse effects was observed between the groups . Mean I‐PSS and I‐PSS quality of life scores , and OABSS significantly improved in both groups . Statistically significantly greater improvement in the silodosin group than in the naftopidil group was observed in total OABSS ( p = 0.03 ) , I‐PSS quality of life score ( p = 0.005 ) and OABSS urgency score ( p < 0.001 ) at 12 weeks . In regard to voiding function the maximum urinary flow rate showed significant improvements in both groups but the change in the maximum flow rate in the silodosin group at 12 weeks was significantly greater than in the naftopidil group ( 3.6 vs 2.1 ml per second ) . Conclusions : Silodosin , a pure & agr;1A‐adrenoceptor blocker , showed greater improvement in overactive bladder symptoms along with the urinary flow rate in patients with benign prostatic enlargement complicated by overactive bladder compared to naftopidil , an & agr;1D > A‐adrenoceptor blocker
Naftopidil appears to have similar effects in the urological symptom scores and QoL compared to tamsulosin and silodosin .
Naftopidil has similar sexual adverse events compared to tamsulosin but has fewer compared to silodosin
BACKGROUND Benign prostatic hyperplasia ( BPH ) is a common condition in ageing men that may cause lower urinary tract symptoms ( LUTS ) .
Treatment aims are to relieve symptoms and prevent disease-related complications .
Naftopidil is an alpha-blocker ( AB ) that has a high affinity for the A1d receptor that may have advantages in treating LUTS in this setting .
This is an up date of a Cochrane Review first published in 2009 .
Since that time , several large r and omised controlled trials ( RCTs ) have been reported , making this up date relevant .
OBJECTIVES To evaluate the effects of naftopidil for the treatment of LUTS associated with BPH .